Philip J. Barter
General / Preventive / Lipids
The University of Sydney
About
Philip J. Barter works in General / Preventive / Lipids affiliated with The University of Sydney.
Philip J. Barter, M.D., Ph.D., was a lipidologist and former Scientific Director and CEO of the Heart Research Institute in Sydney, Australia. He chaired major international trials including ILLUMINATE (torcetrapib) and dal-OUTCOMES (dalcetrapib) and contributed to the TNT study on atorvastatin. He held affiliations with institutions including the University of Sydney and consulted for AstraZeneca.
Research focus
CETP inhibitors and HDL metabolismIntensive LDL cholesterol lowering with statinsVisceral obesity and cardiovascular riskLipoprotein metabolism in diabetes and metabolic syndromeClinical trials in atherosclerosis and coronary disease
Impact
594 pubs · 60,519 cites · h-index 99
Training
MBBS
University of Adelaide
PhD
Australian National University
Affiliations
Work Experience
Heart Research Institute, Sydney
2026
Heart Research Institute, Sydney
AstraZeneca